Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie

Schoretsanitis Georgios; Kane John M.; Correll Christoph U.; Marder Stephen R.; Citrome Leslie; Newcomer John W.; Robinson Delbert G.; Goff Donald C.; Kelly Deanna L.; Freudenreich Oliver; Piacentino Daria; Paulzen Michael; Conca Andreas; Zernig Gerald; Haen Ekkehard; Baumann Pierre; Hiemke Christoph; Grunder Gerhard

首页> 外文期刊>The journal of clinical psychiatry >Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie

【24h】

Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie

机译：血液水平优化临床实践中的抗精神病药治疗：Arbeitsgemeinschaft Fur Neuropscharogie und PharmakogsChiaverie的美国临床精神医学和治疗药物监测工作队的联合共识声明

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective: The quantification of antipsychotic levels in blood, also known as therapeutic drug monitoring (TDM), is a potentially useful tool of modern personalized therapy that can be applied to augment antipsychotic use and dosing decisions. The application of TDM for antipsychotics can be helpful in numerous challenging clinical scenarios, such as lack of therapeutic response, relapse, or adverse drug reactions (ADRs) related to antipsychotic treatment. The benefits of TDM may be particularly evident in the treatment of highly vulnerable patient subgroups, such as children, adolescents, pregnant women, and the elderly. The main aim of this article is to aid clinicians who routinely prescribe antipsychotics to successfully apply TDM in routine clinical practice in order to help optimize the efficacy and safety of those antipsychotics.

机译：目的：血液中抗精神病药物水平的量化，也称为治疗药物监测（TDM），是现代个性化治疗的潜在有用工具，可用于增加抗精神病药物的使用和剂量决定。TDM在抗精神病药物中的应用在许多具有挑战性的临床场景中都有帮助，例如缺乏治疗反应、复发或与抗精神病药物治疗相关的药物不良反应（ADR）。TDM的好处可能在治疗高度脆弱的患者亚群时尤其明显，如儿童、青少年、孕妇和老年人。本文的主要目的是帮助常规处方抗精神病药物的临床医生在常规临床实践中成功应用TDM，以帮助优化这些抗精神病药物的疗效和安全性。

著录项

来源
《The journal of clinical psychiatry》 |2020年第3期|共11页
作者
Schoretsanitis Georgios; Kane John M.; Correll Christoph U.; Marder Stephen R.; Citrome Leslie; Newcomer John W.; Robinson Delbert G.; Goff Donald C.; Kelly Deanna L.; Freudenreich Oliver; Piacentino Daria; Paulzen Michael; Conca Andreas; Zernig Gerald; Haen Ekkehard; Baumann Pierre; Hiemke Christoph; Grunder Gerhard;
展开▼
作者单位

Northwell Hlth Zucker Hillside Hosp Dept Psychiat Glen Oaks NY 11004 USA;

Northwell Hlth Zucker Hillside Hosp Dept Psychiat Glen Oaks NY 11004 USA;

Northwell Hlth Zucker Hillside Hosp Dept Psychiat Glen Oaks NY 11004 USA;

Univ Calif Los Angeles David Geffen Sch Med Psychiat &

Biobehav Sci Los Angeles CA 90095 USA;

New York Med Coll Dept Psychiat &

Behav Sci Valhalla NY 10595 USA;

Thriving Mind South Florida Behav Hlth Network Miami FL USA;

Northwell Hlth Zucker Hillside Hosp Dept Psychiat Glen Oaks NY 11004 USA;

NYU Langone Med Ctr Dept Psychiat New York NY USA;

Univ Maryland Sch Med Dept Psychiat Baltimore MD 21201 USA;

Harvard Med Sch Massachusetts Gen Hosp Dept Psychiat Boston MA 02115 USA;

NIAAA Sect Clin Psychoneuroendocrinol &

Neuropsychophar Div Intramural Clin &

Biol Res Bethesda;

Alexianer Hosp Aachen Aachen Germany;

Serv Psichiatr Comprensorio Sanit Bolzano Bolzano Italy;

Med Univ Innsbruck Dept Psychiat &

Psychotherapy Expt Psychiat Unit Innsbruck Austria;

Univ Regensburg Clin Pharmacol Dept Psychiat &

Psychotherapy Regensburg Germany;

Univ Lausanne Dept Psychiat Prilly Switzerland;

Univ Med Ctr Mainz Dept Psychiat &

Psychotherapy Mainz Germany;

Heidelberg Univ Med Fac Mannheim Cent Inst Mental Hlth Dept Mol Neuroimaging Mannheim Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类精神病学;
关键词

相似文献

外文文献

1. Competence to give informed consent to clinical studies. Statement by the taskforce on "ethical and legal questions" of the Association for Neuropsychopharmacology and Pharmacopsychiatry ("Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmako [J] . Nedopil N, Aldenhoff J, Amelung K, Pharmacopsychiatry . 1999,第5期

机译：给予临床研究知情同意的能力。工作组关于神经精神药理学和药物精神病学协会（“神经精神药理学和药物学”的“道德和法律问题”的声明）的声明
2. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring [J] . Kenji Okada, Toshimi Kimura, Hiroshige Mikamo, Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy . 2014,第1a2期

机译：阿贝卡星治疗药物监测的临床实践指南：日本化学治疗学会和日本治疗药物监测学会的共识性评论
3. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. [J] . Aronow WS, Fleg JL, Pepine CJ, Journal of the American College of Cardiology . 2011,第20期

机译：ACCF / AHA 2011年有关老年人高血压的专家共识文件：美国心脏病学会基金会临床专家共识特别工作组的报告，该文件是与美国神经病学研究院，美国老年医学会，美国预防心脏病学会，美国高血压学会，美国肾脏病学会，黑人心脏病学家协会和欧洲高血压学会。
4. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas the United States Cutaneous Lymphoma Consortium and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer [O] . Elise A. Olsen, Sean Whittaker, Youn H. Kim, -1

机译：真菌病和塞氏病综合症的临床终点和反应标准：国际皮肤性淋巴瘤学会美国皮肤性淋巴瘤协会和欧洲癌症研究与治疗组织的皮肤性淋巴瘤工作队的共识声明
5. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)44The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur.55This document was approved by the American College of Cardiology Foundation Board of Trustees in July, 2003, the American Heart Association Science Advisory and Coordinating Committee in July, 2003, and the American Society of Nuclear Cardiology Board of Directors in July, 2003.66When citing this document, the American College of Cardiology Foundation, the American Heart Association, and the American Society of Nuclear Cardiology request that the following citation format be used: Klocke FJ, Baird MG, Bateman TM, Berman DS, Carabello BA, Cerqueira MD, DeMaria AN, Kennedy JW, Lorell BH, Messer JV, O’Gara PT, Russell RO Jr, St. John Sutton MG, Udelson JE, Verani MS, Williams KA. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol 2003;42:1318–33.77(J Am Coll Cardiol 2003;42:1318–33)88©2003 by the American College of Cardiology Foundation and the American Heart Association, Inc. [O] . Klocke Francis J, Baird Michael G, Lorell Beverly H, 2003

机译：ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要美国心脏病学会/美国心脏协会实践指南工作组的报告（ACC / AHA / ASNC委员会，对1995年临床使用指南进行修订ACC / AHA实践指导小组）竭尽全力避免由于写作小组成员的外部关系或个人利益而引起的任何实际或潜在的利益冲突。具体来说，要求写作小组的所有成员提供所有可能被视为实际或潜在利益冲突的关系的披露声明。这些声明由上级工作组审查，在第一次会议上向书面小组的所有成员口头报告，并在发生变化时进行更新。55本文件于2003年7月获得美国心脏病学会基金会董事会的批准。 2003年7月，美国心脏协会科学咨询与协调委员会，2003年7月，美国核心脏病学会理事会。66引用该文件时，美国心脏病学会基金会，美国心脏协会和美国核学会心脏病学要求使用以下引用格式：Klocke FJ，Baird MG，Bateman TM，Berman DS，Carabello BA，Cerqueira MD，DeMaria AN，Kennedy JW，Lorell BH，Messer JV，O'Gara PT，Russell RO Jr，St John Sutton MG，Udelson JE，Verani MS，Williams KA。 ACC / AHA / ASNC心脏放射性核素成像临床使用指南-执行摘要：美国心脏病学会/美国心脏协会实践小组工作指南（ACC / AHA / ASNC委员会，修订1995年临床指南）的报告使用放射性核素成像）。 J Am Coll Cardiol 2003; 42：1318–33.77（J Am Coll Cardiol 2003; 42：1318–33）88©2003美国心脏病学会基金会和美国心脏协会版权所有。

Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie

摘要

著录项

相似文献

相关主题

期刊订阅